Published in J Gastroenterol Hepatol on January 01, 2012
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer (2008) 4.09
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int (2009) 2.86
Hepatitis B in China. Lancet (2007) 2.67
Survival prediction of gastric cancer by a seven-microRNA signature. Gut (2009) 2.37
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28
How to solve the crisis behind Bribegate for Chinese doctors. Lancet (2011) 2.27
Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int (2013) 2.22
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol (2010) 2.11
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun (2010) 1.80
Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol (2010) 1.79
Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res (2011) 1.68
Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes. Am J Hematol (2007) 1.66
Find duplicates among the PubMed, EMBASE, and Cochrane Library Databases in systematic review. PLoS One (2013) 1.63
Prevalence of covert duplicate publications in Budd-Chiari syndrome articles in China: a systematic analysis. Am J Med (2013) 1.63
Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun (2004) 1.63
TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol Ther (2006) 1.57
Effect of a novel inhibitory mAb against beta-subunit of F1F0 ATPase on HCC. Cancer Biol Ther (2008) 1.54
Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis. Intern Emerg Med (2014) 1.52
Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. J Gastroenterol Hepatol (2012) 1.51
Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther (2004) 1.51
MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One (2011) 1.51
Transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome: a critical review of literatures. Scand J Gastroenterol (2013) 1.50
Human mitochondrial Mrs2 protein promotes multidrug resistance in gastric cancer cells by regulating p27, cyclin D1 expression and cytochrome C release. Cancer Biol Ther (2009) 1.50
Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol (2013) 1.49
Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci (2007) 1.48
MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis (2010) 1.45
Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther (2004) 1.44
Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature. Eur J Gastroenterol Hepatol (2015) 1.43
Helicobacter pylori infection may improve the survival of patients with carcinomas. Med Hypotheses (2007) 1.40
Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology (2013) 1.39
Two hypotheses for decreasing hepatic encephalopathy risk after transjugular intrahepatic portosystemic shunt. Hepatology (2010) 1.39
Up-regulation of tumor suppressor genes might promote the malignant phenotype of cancer cells. Med Hypotheses (2007) 1.39
Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol (2015) 1.33
MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis (2011) 1.30
Dysregulation of cellular signaling in gastric cancer. Cancer Lett (2010) 1.29
The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg (2010) 1.28
MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun (2013) 1.25
Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J (2006) 1.23
Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol (2012) 1.22
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology (2014) 1.22
Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med (2012) 1.21
miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett (2013) 1.21
Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One (2012) 1.20
The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis (2012) 1.20
MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS One (2012) 1.20
Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol (2009) 1.18
Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther (2007) 1.17
Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int J Cancer (2005) 1.16
KLF8 involves in TGF-beta-induced EMT and promotes invasion and migration in gastric cancer cells. J Cancer Res Clin Oncol (2013) 1.16
MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med (2011) 1.15
PALS1 specifies the localization of ezrin to the apical membrane of gastric parietal cells. J Biol Chem (2005) 1.15
Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res (2007) 1.14
Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther (2010) 1.14
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer (2012) 1.13
Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J (2007) 1.13
Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology (2012) 1.12
Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study. J Gastroenterol Hepatol (2012) 1.12
Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp Cell Res (2004) 1.12
Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage? J Clin Oncol (2014) 1.10
Hepatopulmonary Syndrome. Dig Dis Sci (2015) 1.10
Gankyrin promotes the proliferation of human pancreatic cancer. Cancer Lett (2010) 1.10
Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer (2010) 1.09
Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med (2009) 1.08
Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res (2004) 1.08
Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett (2002) 1.08
Midodrine for paracentesis-induced circulatory dysfunction. J Clin Gastroenterol (2014) 1.08
MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets (2013) 1.07
The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Dig Dis Sci (2008) 1.07
Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun (2005) 1.07
Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol (2013) 1.07
MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci (2013) 1.06
Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. FASEB J (2013) 1.06
Prevalence of paroxysmal nocturnal hemoglobinuria in Chinese patients with Budd-Chiari syndrome or portal vein thrombosis. J Gastroenterol Hepatol (2013) 1.06
Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis (2008) 1.05
Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma. Biochem Biophys Res Commun (2007) 1.05
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer (2014) 1.04